CD274 and head and neck squamous cell carcinoma: Clinical findings in the HNSCC cohort of the KEYNOTE-012 study showed that patients with both elevated TMB and high PD-L1 expression responded to treatment with pembrolizumab; moreover, there was no direct association between TMB and PD-L1 expression.